Evidence map›Paper›PMID 39251553›Full record

ArticleDrug delivery and translational research2025

Biomimetic modification of macrophage membrane-coated prussian blue nanoparticles loaded with SN-38 to treat colorectal cancer by photothermal-chemotherapy.

Xuyang Hou, Zuxing Wei, Xiaoyan Qi, Dekun Liu, Yin Sun, Yuhong Jiang, Chao Liu, Weihan Zhou, Leping Yang, Kuijie Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xuyang HouDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Zuxing WeiDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Xiaoyan QiDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Dekun LiuDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Yin SunDepartment of of Pharmaceutical Pharmacology, University of South China, Hengyang, Hunan, China.
Yuhong JiangDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Chao LiuDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Weihan ZhouDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Leping YangDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Kuijie LiuDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China. liukuijie@csu.edu.cn.

Funding

Hunan Provincial Health Commission 202204014332
6 · The paper itself

Abstract

SN-38 is the active metabolite of irinotecan and acts as an effective topoisomerase I inhibitor with therapeutic effects on many malignant tumors, including some drug-resistant cancers. However, the poor solubility, low bioavailability, and severe dose-dependent toxicity limits the clinical application of SN-38. Currently, emerging macrophage membrane-coated nanoparticles provide an efficient biomimetic approach to develop novel SN-38 formulations for the reduction of its side effects. Photothermal therapy (PTT) is a promising methods in tumor treatment to thermally ablate tumors using various materials such Prussian blue nanoparticles (NPs) and can combined with chemotherapy to synergistically work. There is no report that combined SN38 and photothermal therapy for the treatment of colorectal cancer (CRC). SN38-PB@CM NPs were constructed by loading SN-38 into macrophage cell membrane-coated hollow mesoporous Prussian blue (PB) NPs. The morphology, size and zeta potential were evaluated by transmission microscopy and dynamic light scatter (DLS). Coomassie bright blue staining was performed to assess total protein profile. The photothermal properties of it were also investigated via near-infrared imaging. CCK8 and calcein-AM/PI staining were used to evaluate cell viability. Flow cytometry was performed to assess cell apoptosis. The fluorescent microscopy was used to observe cellular uptake of SN38-PB@CM NPs to assess its internalization in vitro. The biodistribution, tumor-targeting efficacy, antitumor efficacy and safety of SN38-PB@CM NPs in vivo were assessed in CT26 tumor-bearing mice via In Vivo Imaging System. SN38-PB@CM NPs were successfully constructed and exhibited a uniform size distribution (140.5 ± 4.3 nm) and an excellent drug-loading capacity (5.61 ± 0.64%). SN38-PB@CM NPs showed stable release properties within 72 h. It can also enhance the selective intracellular delivery of SN38 in vitro and showed good near-infrared (NIR) photothermal properties. And the NPs showed excellent tumor targeting, effective photothermal therapy, improved biosafety and antitumor efficacy on CT26-bearing mice. Multifunctional SN38-PB@CM NPs could achieve improved biosafety, great tumor-targeting, high-efficiency PTT and excellent antitumor efficacy, which provided a promising and attractive combination therapy for the treatment of CRC.

Indexed as

Antineoplastic Agents, PhytogenicColorectal NeoplasmsFerrocyanidesIrinotecanNanoparticlesTopoisomerase I InhibitorsAnimalsCell Line, TumorCell MembraneCell SurvivalDrug LiberationHumansMacrophagesMiceMice, Inbred BALB CPhotothermal TherapyAntineoplastic Agents, Phytogenicferric ferrocyanideFerrocyanidesIrinotecanTopoisomerase I InhibitorsBiomimeticChemotherapyColorectal cancerPhotothermal therapySN-38

Identifiers

PMID39251553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.